azelastine has been researched along with Adverse Drug Event in 4 studies
azelastine: azeptin is azelastine hydrochloride; structure; eye drop formulation effective in relieving symptoms of allergic conjunctivitis; do not confuse with 5-loxin which is an extract of Boswellia
azelastine : A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The safety of a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) has been established in adults and adolescents with allergic rhinitis but not in children <12 years old." | 5.27 | Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial. ( Berger, W; Fineman, S; Gawchik, S; Sher, E, 2018) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Berger, W | 1 |
| Sher, E | 1 |
| Gawchik, S | 1 |
| Fineman, S | 1 |
| Kelso, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Trial of the Safety of Dymista Nasal Spray and Fluticasone Propionate Nasal Spray in Children Ages >4 Years to <12 Years With Allergic Rhinitis[NCT01794741] | Phase 3 | 405 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
reports of treatment emergent adverse events (NCT01794741)
Timeframe: 3 months of treatment
| Intervention | event (Number) |
|---|---|
| Dymista Nasal Spray | 124 |
| Fluticasone Nasal Spray | 37 |
2 trials available for azelastine and Adverse Drug Event
| Article | Year |
|---|---|
Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial.
Topics: Administration, Intranasal; Anti-Allergic Agents; Child; Child, Preschool; Drug-Related Side Effects | 2018 |
Study protocol on azelastine.
Topics: Anti-Allergic Agents; Chlorpheniramine; Data Interpretation, Statistical; Double-Blind Method; Drug | 1997 |
2 other studies available for azelastine and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |